Recent from talks
Nothing was collected or created yet.
Hypothyroidism
View on Wikipedia
| Hypothyroidism | |
|---|---|
| Other names | Underactive thyroid, low thyroid, hypothyreosis |
| Molecular structure of thyroxine, which is deficient in hypothyroidism | |
| Pronunciation | |
| Specialty | Endocrinology |
| Symptoms | Fatigue (feeling tired), poor ability to tolerate cold, muscle aches, constipation, weight gain,[3] depression, anxiety, irritability[4] |
| Complications | During pregnancy can result in cretinism in the baby[5] |
| Usual onset | > 60 years old[3] |
| Causes | Hashimoto's thyroiditis, thyroiditis, surgical removal of thyroid gland, iodine deficiency, lithium treatment[3] |
| Diagnostic method | Blood tests (thyroid-stimulating hormone, thyroxine)[3] |
| Differential diagnosis | Depression, dementia, heart failure, chronic fatigue syndrome[6] |
| Prevention | Salt iodization[7] |
| Treatment | Levothyroxine[3] |
| Frequency | 0.3–0.4%[8] |
Hypothyroidism is an endocrine disease in which the thyroid gland does not produce enough thyroid hormones.[3] It can cause a number of symptoms, such as poor ability to tolerate cold, extreme fatigue, muscle aches, constipation, slow heart rate, depression, and weight gain.[3] Occasionally there may be swelling of the front part of the neck due to goiter.[3] Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.[5]
Worldwide, too little iodine in the diet is the most common cause of hypothyroidism.[8][9] Hashimoto's thyroiditis, an autoimmune disease where the body's immune system reacts to the thyroid gland,[10] is the most common cause of hypothyroidism in countries with sufficient dietary iodine.[3] Less common causes include previous treatment with radioactive iodine, injury to the hypothalamus or the anterior pituitary gland, certain medications, a lack of a functioning thyroid at birth, or previous thyroid surgery.[3][11] The diagnosis of hypothyroidism, when suspected, can be confirmed with blood tests measuring thyroid-stimulating hormone (TSH) and thyroxine (T4) levels.[3]
Salt iodization has prevented hypothyroidism in many populations.[7] Thyroid hormone replacement with levothyroxine treats hypothyroidism.[3] Medical professionals adjust the dose according to symptoms and normalization of the TSH levels.[12] Thyroid medication is safe in pregnancy.[3] Although an adequate amount of dietary iodine is important, too much may worsen specific forms of hypothyroidism.[3]
Worldwide about one billion people are estimated to be iodine-deficient; however, it is unknown how often this results in hypothyroidism.[13] In the United States, overt hypothyroidism occurs in approximately 0.3–0.4% of people.[8] Subclinical hypothyroidism, a milder form of hypothyroidism characterized by normal thyroxine levels and an elevated TSH level, is thought to occur in 4.3–8.5% of people in the United States.[8] Hypothyroidism is more common in women than in men.[3] People over the age of 60 are more commonly affected.[3] Dogs are also known to develop hypothyroidism, as are cats and horses, albeit more rarely.[14] The word hypothyroidism is from Greek hypo- 'reduced', thyreos 'shield', and eidos 'form', where the two latter parts refer to the thyroid gland.[15]
Signs and symptoms
[edit]People with hypothyroidism often have no or only mild symptoms. Numerous symptoms and signs are associated with hypothyroidism and can be related to the underlying cause, or a direct effect of not having enough thyroid hormones.[16][17] Many symptoms of hypothyroidism are otherwise common and do not necessarily indicate thyroid problem.[3] Hashimoto's thyroiditis may present with the mass effect of a goiter (enlarged thyroid gland).[16] In middle-aged women, the symptoms may be mistaken for those of menopause.[12]

| Symptoms[16] | Signs[16] |
|---|---|
| Fatigue | Dry, coarse skin |
| Feeling cold | Cool extremities |
| Poor memory and concentration | Myxedema (mucopolysaccharide deposits in the skin) |
| Constipation, dyspepsia[18] | Hair loss, Sign of Hertoghe |
| Weight gain with poor appetite | Slow pulse rate |
| Shortness of breath | Swelling of the limbs |
| Hoarse voice | Delayed relaxation of tendon reflexes |
| In females, heavy menstrual periods (and later light periods) | Carpal tunnel syndrome |
| Abnormal sensation | Pleural effusion, ascites, pericardial effusion |
| Poor hearing | |
| Muscle weakness |
Delayed relaxation after testing the ankle jerk reflex is a characteristic sign of hypothyroidism and is associated with the severity of the hormone deficit.[8]
Myxedema coma
[edit]Myxedema coma is a rare but life-threatening state of extreme hypothyroidism. It may occur in those with established hypothyroidism when they develop an acute illness. Myxedema coma can be the first presentation of hypothyroidism. People with myxedema coma typically have a low body temperature without shivering, confusion, a slow heart rate and reduced breathing effort. There may be physical signs suggestive of hypothyroidism, such as skin changes or enlargement of the tongue.[19]
Pregnancy
[edit]Hypothyroidism when untreated may lead to infertility and an increased risk of miscarriage or infant death around the time of birth, mostly in severe cases of hypothyroidism.[20][21] Women are affected by hypothyroidism in 0.3–0.5% of pregnancies.[22] Subclinical hypothyroidism during pregnancy is associated with birth of the baby before 37 weeks of pregnancy.[23]
Children
[edit]Newborn children with hypothyroidism may have normal birth weight and height (although the head may be larger than expected and the posterior fontanelle may be open). Some may have drowsiness, decreased muscle tone, poor weight gain, a hoarse-sounding cry, feeding difficulties, constipation, an enlarged tongue, umbilical hernia, dry skin, a decreased body temperature, and jaundice.[24] A goiter is rare, although it may develop later in children who have a thyroid gland that does not produce functioning thyroid hormone.[24] A goiter may also develop in children growing up in areas with iodine deficiency.[25] Normal growth and development may be delayed, and not treating infants may lead to an intellectual impairment (IQ 6–15 points lower in severe cases). Other problems include the following: difficulty with large scale and fine motor skills and coordination, reduced muscle tone, squinting, decreased attention span, and delayed speaking.[24] Tooth eruption may be delayed.[26]
In older children and adolescents, the symptoms of hypothyroidism may include fatigue, cold intolerance, sleepiness, muscle weakness, constipation, a delay in growth, overweight for height, pallor, coarse and thick skin, increased body hair, irregular menstrual cycles in girls, and delayed puberty. Signs may include delayed relaxation of the ankle reflex and a slow heartbeat.[24] A goiter may be present with a completely enlarged thyroid gland;[24] sometimes only part of the thyroid is enlarged and it can be knobby.[27]
Causes
[edit]Hypothyroidism is caused by inadequate function of the gland itself (primary hypothyroidism), inadequate stimulation by thyroid-stimulating hormone from the pituitary gland (secondary hypothyroidism), or inadequate release of thyrotropin-releasing hormone from the brain's hypothalamus (tertiary hypothyroidism).[8][28] Primary hypothyroidism is about a thousandfold more common than central hypothyroidism.[11] Central hypothyroidism is the name used for secondary and tertiary hypothyroidism since the hypothalamus and pituitary gland are at the center of thyroid hormone control.
Iodine deficiency is the most common cause of primary hypothyroidism and endemic goiter worldwide.[8][9] In areas of the world with sufficient dietary iodine, hypothyroidism is most commonly caused by the autoimmune disease Hashimoto's thyroiditis (chronic autoimmune thyroiditis).[8][9] Hashimoto's may be associated with a goiter. It is characterized by infiltration of the thyroid gland with T lymphocytes and autoantibodies against specific thyroid antigens such as thyroid peroxidase, thyroglobulin and the TSH receptor.[8]
After women give birth, about 5% develop postpartum thyroiditis which can occur up to nine months afterwards.[29] This is characterized by a short period of hyperthyroidism followed by a period of hypothyroidism; 20–40% remain permanently hypothyroid.[29]
Autoimmune thyroiditis (Hashimoto's) is associated with other immune-mediated diseases such as diabetes mellitus type 1, pernicious anemia, myasthenia gravis, celiac disease, rheumatoid arthritis and systemic lupus erythematosus.[8] It may occur as part of autoimmune polyendocrine syndrome (type 1 and type 2).[8]
Iatrogenic hypothyroidism can be surgical (a result of thyroidectomy, usually for thyroid nodules or cancer) or following radioiodine ablation (usually for Graves' disease).
| Type of hypothyroidism | Causes |
|---|---|
| Primary hypothyroidism[8] | Iodine deficiency (developing countries), autoimmune thyroiditis, subacute granulomatous thyroiditis, subacute lymphocytic thyroiditis, postpartum thyroiditis, previous thyroidectomy, acute infectious thyroiditis,[30] previous radioiodine treatment, previous external beam radiotherapy to the neck Medication: lithium-based mood stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib |
| Central hypothyroidism[11] | Lesions compressing the pituitary (pituitary adenoma, craniopharyngioma, meningioma, glioma, Rathke's cleft cyst, metastasis, empty sella, aneurysm of the internal carotid artery), surgery or radiation to the pituitary, drugs, injury, vascular disorders (pituitary apoplexy, Sheehan syndrome, subarachnoid hemorrhage), autoimmune diseases (lymphocytic hypophysitis, polyglandular disorders), infiltrative diseases (iron overload due to hemochromatosis or thalassemia, neurosarcoidosis, Langerhans cell histiocytosis), particular inherited congenital disorders, and infections (tuberculosis, mycoses, syphilis) |
| Congenital hypothyroidism[31] | Thyroid dysgenesis (75%), thyroid dyshormonogenesis (20%), maternal antibody or radioiodine transfer Syndromes: mutations (in GNAS complex locus, PAX8, TTF-1/NKX2-1, TTF-2/FOXE1), Pendred's syndrome (associated with sensorineural hearing loss) Transiently: due to maternal iodine deficiency or excess, anti-TSH receptor antibodies, certain congenital disorders, neonatal illness Central: pituitary dysfunction (idiopathic, septo-optic dysplasia, deficiency of PIT1, isolated TSH deficiency) |
Pathophysiology
[edit]
Thyroid hormone is required for the normal functioning of numerous tissues in the body. In healthy individuals, the thyroid gland predominantly secretes thyroxine (T4), which is converted into triiodothyronine (T3) in other organs by the selenium-dependent enzyme iodothyronine deiodinase.[32] Triiodothyronine binds to the thyroid hormone receptor in the nucleus of cells, where it stimulates the turning on of particular genes and the production of specific proteins.[33] Additionally, the hormone binds to integrin αvβ3 on the cell membrane, thereby stimulating the sodium–hydrogen antiporter and processes such as formation of blood vessels and cell growth.[33] In blood, almost all thyroid hormone (99.97%) are bound to plasma proteins such as thyroxine-binding globulin; only the free unbound thyroid hormone is biologically active.[8]
Electrocardiograms are abnormal in both primary overt hypothyroidism and subclinical hypothyroidism.[34] T3 and TSH are essential for the regulation of cardiac electrical activity.[34] Prolonged ventricular repolarization and atrial fibrillation are often seen in hypothyroidism.[34]
The thyroid gland is the only source of thyroid hormone in the body; the process requires iodine and the amino acid tyrosine. The gland takes up iodine in the bloodstream and incorporates it into thyroglobulin molecules. The process is controlled by the thyroid-stimulating hormone (TSH, thyrotropin), which is secreted by the pituitary. Not enough iodine, or not enough TSH, can decrease thyroid hormone production.[28]
The hypothalamic–pituitary–thyroid axis plays a key role in maintaining thyroid hormone levels within normal limits. Production of TSH by the anterior pituitary gland is stimulated in turn by thyrotropin-releasing hormone (TRH), released from the hypothalamus. Production of TSH and TRH is decreased by thyroxine by a negative feedback process. Not enough TRH, which is uncommon, can lead to insufficient TSH release and therefore insufficient thyroid hormone production.[11]
Pregnancy leads to marked changes in thyroid hormone physiology. The gland increases in size by 10%, thyroxine production increases by 50%, and iodine requirements increase. Many women have normal thyroid function but have immunological evidence of thyroid autoimmunity (as evidenced by autoantibodies) or are iodine-deficient, and develop evidence of hypothyroidism before or after giving birth.[35]
Diagnosis
[edit]Laboratory testing of thyroid stimulating hormone (TSH) levels in the blood is considered the best initial test for hypothyroidism; a second TSH level is often obtained several weeks later for confirmation.[36] Levels may be abnormal in the context of other illnesses, and TSH testing in hospitalized people is discouraged unless thyroid dysfunction is strongly suspected[8] as the cause of the acute illness.[12] An elevated TSH level indicates that the thyroid gland is not producing enough thyroid hormone, and free T4 levels are then often obtained.[8][12][27] Measuring T3 in the assessment for hypothyroidism is discouraged by the American Association of Clinical Endocrinologists (AACE) and National Institute for Health and Care Excellence (NICE).[8] NICE recommends routine T4 testing in children where clinically indicated, and in adults only if central hypothyroidism is suspected or the TSH is abnormal.[12] There are several symptom rating scales for hypothyroidism; they provide a degree of objectivity but have limited use for diagnosis.[8]
| TSH | T4 | Interpretation |
|---|---|---|
| Normal | Normal | Normal thyroid function |
| Elevated | Low | Overt hypothyroidism |
| Normal/low | Low | Central hypothyroidism |
| Elevated | Normal | Subclinical hypothyroidism |
Many cases of hypothyroidism are associated with mild elevations in creatine kinase and liver enzymes in the blood. They typically return to normal when hypothyroidism has been fully treated.[8] Levels of cholesterol, low-density lipoprotein and lipoprotein (a) can be elevated;[8] the impact of subclinical hypothyroidism on lipid parameters is less well-defined.[25]
Very severe hypothyroidism and myxedema coma are characteristically associated with low sodium levels in the blood together with elevations in antidiuretic hormone, as well as acute worsening of kidney function due to several causes.[19] For most causes, however, it is unclear if the relationship is causal.[37]
A diagnosis of hypothyroidism without any lumps or masses felt within the thyroid gland does not require thyroid imaging; however, if the thyroid feels abnormal, diagnostic imaging is then recommended.[36] The presence of antibodies against thyroid peroxidase (TPO) makes it more likely that thyroid nodules are caused by autoimmune thyroiditis, but if there is any doubt, a needle biopsy may be required.[8]
Central
[edit]If the TSH level is normal or low and serum free T4 levels are low, this is suggestive of central hypothyroidism (not enough TSH or TRH secretion by the pituitary gland or hypothalamus, respectively). There may be other features of hypopituitarism, such as menstrual cycle abnormalities and adrenal insufficiency. There might also be symptoms of a pituitary mass such as headaches and vision changes. Central hypothyroidism should be investigated further to determine the underlying cause.[11][36]
Overt
[edit]In overt primary hypothyroidism, TSH levels are high and T4 levels are low. Overt hypothyroidism may also be diagnosed in those who have a TSH on multiple occasions of greater than 5mIU/L, appropriate symptoms, and only a borderline low T4.[38] It may also be diagnosed in those with a TSH of greater than 10mIU/L.[38]
Subclinical
[edit]Subclinical hypothyroidism is a biochemical diagnosis characterized by an elevated serum TSH level, but with a normal serum free thyroxine level.[39][40][41] The incidence of subclinical hypothyroidism is estimated to be 3-15% and a higher incidence is seen in elderly people, females and those with lower iodine levels.[39] Subclinical hypothyroidism is most commonly caused by autoimmune thyroid diseases, especially Hashimoto's thyroiditis.[42] The presentation of subclinical hypothyroidism is variable and classic signs and symptoms of hypothyroidism may not be observed.[40] Of people with subclinical hypothyroidism, a proportion will develop overt hypothyroidism each year. In those with detectable antibodies against thyroid peroxidase (TPO), this occurs in 4.3%, while in those with no detectable antibodies, this occurs in 2.6%.[8] In addition to detectable anti-TPO antibodies, other risk factors for conversion from subclinical hypothyroidism to overt hypothyroidism include female sex or in those with higher TSH levels or lower level of normal free T4 levels.[39] Those with subclinical hypothyroidism and detectable anti-TPO antibodies who do not require treatment should have repeat thyroid function tested more frequently (e.g. every 6 months) compared with those who do not have antibodies.[36][39]
Pregnancy
[edit]During pregnancy, the thyroid gland must produce 50% more thyroid hormone to provide enough thyroid hormone for the developing fetus and the expectant mother.[43] In pregnancy, free thyroxine levels may be lower than anticipated due to increased binding to thyroxine-binding globulin and decreased binding to albumin. They should either be corrected for the stage of pregnancy,[35] or total thyroxine levels should be used instead for diagnosis.[8] TSH values may also be lower than normal (particularly in the first trimester) and the normal range should be adjusted for the stage of pregnancy.[8][35]
In pregnancy, subclinical hypothyroidism is defined as a TSH between 2.5 and 10 mIU/L with a normal thyroxine level, while those with TSH above 10 mIU/L are considered to be overtly hypothyroid even if the thyroxine level is normal.[35] Antibodies against TPO may be important in making treatment decisions, and should, therefore, be determined in women with abnormal thyroid function tests.[8] Determination of TPO antibodies may be considered as part of the assessment of recurrent miscarriage, as subtle thyroid dysfunction can be associated with pregnancy loss,[8] but this recommendation is not universal,[44] and the presence of thyroid antibodies may not predict future outcomes.[45]
Prevention
[edit]
Hypothyroidism may be prevented in a population by adding iodine to commonly used foods. This public health measure has eliminated endemic childhood hypothyroidism in countries where it was once common. In addition to promoting the consumption of iodine-rich foods such as dairy and fish, many countries with moderate iodine deficiency have implemented universal salt iodization.[46] Encouraged by the World Health Organization,[47] 70% of the world's population across 130 countries are receiving iodized salt. In some countries, iodized salt is added to bread.[46] Despite this, iodine deficiency has reappeared in some Western countries due to attempts to reduce salt intake.[46]
Pregnant and breastfeeding women, who require 66% more daily iodine than non-pregnant women, may still not be getting enough iodine.[46][48] The World Health Organization recommends a daily intake of 250 μg for pregnant and breastfeeding women.[49] As many women will not achieve this from dietary sources alone, the American Thyroid Association recommends a 150 μg daily supplement by mouth.[35][50]
Screening
[edit]Screening for hypothyroidism is performed in the newborn period in many countries, generally using TSH. This has led to the early identification of many cases and thus the prevention of developmental delay.[51] It is the most widely used newborn screening test worldwide.[52] While TSH-based screening will identify the most common causes, the addition of T4 testing is required to pick up the rarer central causes of neonatal hypothyroidism.[24] If T4 determination is included in the screening done at birth, this will identify cases of congenital hypothyroidism of central origin in 1:16,000 to 1:160,000 children. Considering that these children usually have other pituitary hormone deficiencies, early identification of these cases may prevent complications.[11]
In adults, widespread screening of the general population is debated. Some organizations (such as the United States Preventive Services Task Force) state that evidence is insufficient to support routine screening,[53] while others (such as the American Thyroid Association) recommend either intermittent testing above a certain age in all sexes or only in women.[8] Targeted screening may be appropriate in a number of situations where hypothyroidism is common: other autoimmune diseases, a strong family history of thyroid disease, those who have received radioiodine or other radiation therapy to the neck, those who have previously undergone thyroid surgery, those with an abnormal thyroid examination, those with psychiatric disorders, people taking amiodarone or lithium, and those with a number of health conditions (such as certain heart and skin conditions).[8] Yearly thyroid function tests are recommended in people with Down syndrome, as they are at higher risk of thyroid disease.[54] Guidelines for England and Wales from the National Institute for Health and Care Excellence (NICE) recommend testing for thyroid disease in people with type 1 diabetes and new-onset atrial fibrillation, and suggests testing in those with depression or unexplained anxiety (all ages), in children with abnormal growth, or unexplained change in behavior or school performance.[12] NICE also recommends screening for celiac disease in people with a diagnosis of autoimmune thyroid disease.[55]
Management
[edit]Hormone replacement
[edit]Hypothyroidism is managed by hormone substitution with a synthetic long-acting form of thyroxine, known as levothyroxine (L-thyroxine).[8][17] In young and otherwise healthy people with overt hypothyroidism, a full replacement dose (adjusted by weight) can be started immediately; in the elderly and people with heart disease a lower starting dose is recommended to prevent oversupplementation and risk of complications.[8][28][12] Lower doses may be sufficient in those with subclinical hypothyroidism, while people with central hypothyroidism may require a higher-than-average dose.[8]
Blood and TSH levels are monitored to help determine whether the dose is adequate. This is done 4–8 weeks after the start of treatment or a change in levothyroxine dose. Once the adequate replacement dose has been established, the tests can be repeated after 6 and then 12 months, unless there is a change in symptoms.[8] Normalization of TSH does not mean that other abnormalities associated with hypothyroidism improve entirely, such as elevated cholesterol levels.[56]
In people with central hypothyroidism, TSH is not a reliable marker of hormone replacement and decisions are based mainly on the free T4 level.[8][11] Levothyroxine is best taken 30–60 minutes before breakfast, or four hours after food,[8] as certain substances such as food and calcium can inhibit the absorption of levothyroxine.[57] There is no direct way of increasing thyroid hormone secretion by the thyroid gland.[17]
Liothyronine
[edit]Treatment with liothyronine (synthetic T3) alone has not received enough study to make a recommendation as to its use; due to its shorter half-life it would need to be taken more often than levothyroxine.[8]
Adding liothyronine to levothyroxine has been suggested as a measure to provide better symptom control, but this has not been confirmed by studies.[9][17][58] In 2007, the British Thyroid Association stated that combined T4 and T3 therapy carried a higher rate of side effects and no benefit over T4 alone.[17][59] Similarly, American guidelines discourage combination therapy due to a lack of evidence, although they acknowledge that some people feel better when receiving combination therapy.[8] Guidelines by National Institute for Health and Care Excellence (NICE) discourage liothyronine.[12]
People with hypothyroidism who do not feel well despite optimal levothyroxine dosing may request adjunctive treatment with liothyronine. A 2012 guideline from the European Thyroid Association recommends that support should be offered concerning the chronic nature of the disease and that other causes of the symptoms should be excluded. The addition of liothyronine should be regarded as experimental, initially only for a trial period of 3 months, and in a set ratio to the current dose of levothyroxine.[60] The guideline explicitly aims to enhance the safety of this approach and to counter its indiscriminate use.[60] A 2014 guideline from the American Thyroid Association recommends against the use of liothyronine.[61]
Desiccated animal thyroid
[edit]Desiccated thyroid extract is an animal-based thyroid gland extract,[17] most commonly from pigs. It is a combination therapy, containing forms of T4 and T3.[17] It also contains calcitonin (a hormone produced in the thyroid gland involved in the regulation of calcium levels), T1 and T2; these are not present in synthetic hormone medication.[62] This extract was once a mainstream hypothyroidism treatment, but has been disregarded since the 1970s and its use is unsupported by evidence;[9][17] British Thyroid Association and American professional guidelines discourage its use,[8][59][61] as does NICE.[12]
Subclinical hypothyroidism
[edit]There is no evidence of a benefit from treating subclinical hypothyroidism in those who are not pregnant, and there are potential risks of unnecessary overtreatment.[63] Untreated subclinical hypothyroidism may be associated with a modest increase in the risk of coronary artery disease when the TSH is over 10 mIU/L.[63][64] There may be an increased risk for cardiovascular death.[65] A 2007 review found no benefit of thyroid hormone replacement except for "some parameters of lipid profiles and left ventricular function".[66] There is no association between subclinical hypothyroidism and an increased risk of bone fractures,[67] nor is there a link with cognitive decline.[68]
American guidelines recommend that treatment should be considered in people with symptoms of hypothyroidism, detectable antibodies against thyroid peroxidase, a history of heart disease, or are at an increased risk for heart disease if the TSH is elevated but below 10 mIU/L.[8] American guidelines further recommend universal treatment (independent of risk factors) in those with TSH levels that are markedly elevated; above 10 mIU/L because of an increased risk of heart failure or death due to cardiovascular disease.[8][39] NICE recommends that those with a TSH above 10 mIU/L should be treated in the same way as overt hypothyroidism. Those with an elevated TSH but below 10 mIU/L who have symptoms suggestive of hypothyroidism should have a trial of treatment but intend to stop this if the symptoms persist despite normalization of the TSH.[12]
Myxedema coma
[edit]Myxedema coma or severe decompensated hypothyroidism usually requires admission to the intensive care unit, close observation and treatment of abnormalities in breathing, temperature control, blood pressure, and sodium levels. Mechanical ventilation may be required, as well as fluid replacement, vasopressor agents, careful rewarming, and corticosteroids (for possible adrenal insufficiency which can occur together with hypothyroidism). Careful correction of low sodium levels may be achieved with hypertonic saline solutions or vasopressin receptor antagonists.[19] For rapid treatment of hypothyroidism, levothyroxine or liothyronine may be administered intravenously, particularly if the level of consciousness is too low to be able to safely swallow medication.[19] While administration through a nasogastric tube is possible, this may be unsafe and is discouraged.[19]
Pregnancy
[edit]In women with known hypothyroidism who become pregnant, it is recommended that serum TSH levels are closely monitored. Levothyroxine should be used to keep TSH levels within the normal range for that trimester. The first-trimester normal range is below 2.5 mIU/L and the second and third trimesters normal range is below 3.0 mIU/L.[17][35] Measurement of free T4 in pregnancy is not recommended due to changes in levels of serum protein binding. Similarly to TSH, the thyroxine results should be interpreted according to the appropriate reference range for that stage of pregnancy.[8] The levothyroxine dose often needs to be increased after pregnancy is confirmed,[8][28][35] although this is based on limited evidence and some recommend that it is not always required; decisions may need to based on TSH levels.[69]
Women with anti-TPO antibodies who are trying to become pregnant (naturally or by assisted means) may require thyroid hormone supplementation even if the TSH level is normal. This is particularly true if they have had previous miscarriages or have been hypothyroid in the past.[8] Supplementary levothyroxine may reduce the risk of preterm birth and possibly miscarriage.[70] The recommendation is stronger in pregnant women with subclinical hypothyroidism (defined as TSH 2.5–10 mIU/L) who are anti-TPO positive, in view of the risk of overt hypothyroidism. If a decision is made not to treat, close monitoring of the thyroid function (every 4 weeks in the first 20 weeks of pregnancy) is recommended.[8][35] If anti-TPO is not positive, treatment for subclinical hypothyroidism is not currently recommended.[35] It has been suggested that many of the aforementioned recommendations could lead to unnecessary treatment, in the sense that the TSH cutoff levels may be too restrictive in some ethnic groups; there may be little benefit from treatment of subclinical hypothyroidism in certain cases.[69] Treatment for subclinical hypothyroidism in pregnancy is not conclusively shown to decrease the incidence of miscarriage.[71][72][73]
Alternative medicine
[edit]The effectiveness and safety of using Chinese herbal medicines to treat hypothyroidism is not known.[74]
Epidemiology
[edit]Hypothyroidism is the most frequent endocrine disorder.[34] Worldwide about one billion people are estimated to be iodine deficient; however, it is unknown how often this results in hypothyroidism.[13] In large population-based studies in Western countries with sufficient dietary iodine, 0.3–0.4% of the population have overt hypothyroidism. A larger proportion, 4.3–8.5%, have subclinical hypothyroidism.[8] Undiagnosed hypothyroidism is estimated to affect about 4–7% of community-derived populations in the US and Europe.[75] Of people with subclinical hypothyroidism, 80% have a TSH level below the 10 mIU/L mark regarded as the threshold for treatment.[41] Children with subclinical hypothyroidism often return to normal thyroid function, and a small proportion develops overt hypothyroidism (as predicted by evolving antibody and TSH levels, the presence of celiac disease, and the presence of a goiter).[76]
Women are more likely to develop hypothyroidism than men. In population-based studies, women were seven times more likely than men to have TSH levels above 10 mU/L.[8] 2–4% of people with subclinical hypothyroidism will progress to overt hypothyroidism each year. The risk is higher in those with antibodies against thyroid peroxidase.[8][41] Subclinical hypothyroidism is estimated to affect approximately 2% of children; in adults, subclinical hypothyroidism is more common in the elderly, and in White people.[40] There is a much higher rate of thyroid disorders, the most common of which is hypothyroidism, in individuals with Down syndrome[24][54] and Turner syndrome.[24]
Very severe hypothyroidism and myxedema coma are rare, with it estimated to occur in 0.22 per million people a year.[19] The majority of cases occur in women over 60 years of age, although it may happen in all age groups.[19]
Most hypothyroidism is primary in nature. Central/secondary hypothyroidism affects 1:20,000 to 1:80,000 of the population or about one out of every thousand people with hypothyroidism.[11]
History
[edit]In 1811, Bernard Courtois discovered iodine was present in seaweed, and iodine intake was linked with goiter size in 1820 by Jean-Francois Coindet.[77] Gaspard Adolphe Chatin proposed in 1852 that endemic goiter was the result of not enough iodine intake, and Eugen Baumann demonstrated iodine in thyroid tissue in 1896.[77]
The first cases of myxedema were recognized in the mid-19th century (the 1870s), but its connection to the thyroid was not discovered until the 1880s when myxedema was observed in people following the removal of the thyroid gland (thyroidectomy).[78] The link was further confirmed in the late 19th century when people and animals who had had their thyroid removed showed improvement in symptoms with transplantation of animal thyroid tissue.[9] The severity of myxedema, and its associated risk of mortality and complications, created interest in discovering effective treatments for hypothyroidism.[78] Transplantation of thyroid tissue demonstrated some efficacy, but recurrences of hypothyroidism was relatively common, and sometimes required multiple repeat transplantations of thyroid tissue.[78]
In 1891, the English physician George Redmayne Murray introduced subcutaneously injected sheep thyroid extract,[79] followed shortly after by an oral formulation.[9][80] Purified thyroxine was introduced in 1914 and in the 1930s synthetic thyroxine became available, although desiccated animal thyroid extract remained widely used. Liothyronine was identified in 1952.[9]
Early attempts at titrating therapy for hypothyroidism proved difficult. After hypothyroidism was found to cause a lower basal metabolic rate, this was used as a marker to guide adjustments in therapy in the early 20th century (around 1915).[78] However, a low basal metabolic rate was known to be non-specific, also present in malnutrition.[78] The first laboratory test to help assess thyroid status was the serum protein-bound iodine, which came into use around the 1950s.
In 1971, the thyroid stimulating hormone (TSH) radioimmunoassay was developed, which was the most specific marker for assessing thyroid status in patients.[78] Many people who were being treated based on basal metabolic rate, minimizing hypothyroid symptoms, or based on serum protein-bound iodine, were found to have excessive thyroid hormone.[78] The following year, in 1972, a T3 radioimmunoassay was developed, and in 1974, a T4 radioimmunoassay was developed.[78]
Other animals
[edit]
In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue.[14][81] There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Skin changes and fertility problems are seen in dogs with hypothyroidism, as well as many other symptoms.[81] The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered.[14] The diagnosis can be confirmed by a blood test, as the clinical impression alone may lead to overdiagnosis.[14][81] Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease.[81] Treatment is with thyroid hormone replacement.[14]
Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatments such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.[14]
References
[edit]- ^ "hypothyroidism". Dictionary.com Unabridged (Online). n.d.
- ^ "hypothyroidism - definition of hypothyroidism in English from the Oxford dictionary". OxfordDictionaries.com. Archived from the original on March 11, 2013. Retrieved 2016-01-20.
- ^ a b c d e f g h i j k l m n o p q "Hypothyroidism". National Institute of Diabetes and Digestive and Kidney Diseases. March 2021. Archived from the original on 11 March 2025. Retrieved 15 March 2025.
- ^ "Psychological symptoms and thyroid disorders". British Thyroid Foundation. 11 September 2019.
- ^ a b Preedy V (2009). Comprehensive Handbook of Iodine Nutritional, Biochemical, Pathological and Therapeutic Aspects. Burlington: Elsevier. p. 616. ISBN 978-0-08-092086-3.
- ^ Ferri FF (2010). Ferri's differential diagnosis: a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia, PA: Elsevier/Mosby. p. Chapter H. ISBN 978-0-323-07699-9.
- ^ a b Syed S (April 2015). "Iodine and the "near" eradication of cretinism". Pediatrics. 135 (4): 594–6. doi:10.1542/peds.2014-3718. PMID 25825529. S2CID 27647943.
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA (December 2012). "Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association". Thyroid. 22 (12): 1200–35. doi:10.1089/thy.2012.0205. PMID 22954017.
- ^ a b c d e f g h Chakera AJ, Pearce SH, Vaidya B (2012). "Treatment for primary hypothyroidism: current approaches and future possibilities". Drug Design, Development and Therapy (Review). 6: 1–11. doi:10.2147/DDDT.S12894. PMC 3267517. PMID 22291465.
- ^ "Hashimoto's Disease". National Institute of Diabetes and Digestive and Kidney Diseases(NIDDK). Retrieved 2024-02-19.
- ^ a b c d e f g h Persani L (September 2012). "Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges". The Journal of Clinical Endocrinology and Metabolism (Review). 97 (9): 3068–78. doi:10.1210/jc.2012-1616. PMID 22851492.
- ^ a b c d e f g h i j "Thyroid disease: assessment and management". www.nice.org.uk. National Institute for Health and Care Excellence. 12 October 2023. Retrieved 15 March 2025.
- ^ a b Cooper, DS, Braverman LE, eds. (2012-07-12). Werner & Ingbar's the thyroid: a fundamental and clinical text (10th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health. p. 552. ISBN 978-1-4511-2063-9. Archived from the original on 2016-05-20.
- ^ a b c d e f "Hypothyroidism". Merck Veterinary Manual, 10th edition (online version). 2012. Archived from the original on 2012-08-23. Retrieved 2013-12-25.
- ^ Mosby's Medical Dictionary (9 ed.). Elsevier Health Sciences. 2013. p. 887. ISBN 978-0-323-11258-1. Archived from the original on 2016-03-07.
- ^ a b c d e Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (2011). "341: disorders of the thyroid gland". Harrison's principles of internal medicine (18th ed.). New York: McGraw-Hill. ISBN 978-0-07-174889-6.
- ^ a b c d e f g h i Khandelwal D, Tandon N (January 2012). "Overt and subclinical hypothyroidism: who to treat and how". Drugs (Review). 72 (1): 17–33. doi:10.2165/11598070-000000000-00000. PMID 22191793. S2CID 207301404.
- ^ Ebert EC (July 2010). "The thyroid and the gut". Journal of Clinical Gastroenterology. 44 (6): 402–6. doi:10.1097/MCG.0b013e3181d6bc3e. PMID 20351569. S2CID 23210397.
- ^ a b c d e f g Klubo-Gwiezdzinska J, Wartofsky L (March 2012). "Thyroid emergencies". The Medical Clinics of North America. 96 (2): 385–403. doi:10.1016/j.mcna.2012.01.015. PMID 22443982.
- ^ "Thyroid disease in Women". Office on Women's Health, U.S. Department of Health and Human Services. December 2017. Archived from the original on 4 March 2025. Retrieved 15 March 2025.
This article incorporates text from this source, which is in the public domain.
- ^ "Postpartum Thyroiditis" (PDF). American Thyroid Association. 2014. Retrieved 20 July 2017.
- ^ Vissenberg R, van den Boogaard E, van Wely M, van der Post JA, Fliers E, Bisschop PH, Goddijn M (July 2012). "Treatment of thyroid disorders before conception and in early pregnancy: a systematic review". Human Reproduction Update (Review). 18 (4): 360–73. doi:10.1093/humupd/dms007. PMID 22431565.
- ^ Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S (March 2017). "2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum". Thyroid. 27 (3): 315–389. doi:10.1089/thy.2016.0457. PMC 3472679. PMID 28056690.
- ^ a b c d e f g h Counts D, Varma SK (July 2009). "Hypothyroidism in children". Pediatrics in Review. 30 (7): 251–8. doi:10.1542/pir.30-7-251. PMID 19570923. S2CID 29460139.
- ^ a b Pearce EN (February 2012). "Update in lipid alterations in subclinical hypothyroidism". The Journal of Clinical Endocrinology and Metabolism. 97 (2): 326–33. doi:10.1210/jc.2011-2532. PMID 22205712.
- ^ Chandna S, Bathla M (July 2011). "Oral manifestations of thyroid disorders and its management". Indian Journal of Endocrinology and Metabolism. 15 (Suppl 2): S113–6. doi:10.4103/2230-8210.83343. PMC 3169868. PMID 21966646.
- ^ a b Brown RS (2013). "Autoimmune thyroiditis in childhood". Journal of Clinical Research in Pediatric Endocrinology (Review). 5 Suppl 1 (4): 45–9. doi:10.4274/jcrpe.855. PMC 3608006. PMID 23154164.
- ^ a b c d Gaitonde DY, Rowley KD, Sweeney LB (August 2012). "Hypothyroidism: an update". American Family Physician. 86 (3): 244–51. PMID 22962987.[permanent dead link]
- ^ a b Stagnaro-Green A (February 2012). "Approach to the patient with postpartum thyroiditis". The Journal of Clinical Endocrinology and Metabolism (Review). 97 (2): 334–42. doi:10.1210/jc.2011-2576. PMID 22312089.
- ^ Shrestha ST, Hennessey J (December 2015). Acute and Subacute, and Riedel's Thyroiditis. MDText.com, Inc. PMID 25905408.
- ^ Donaldson M, Jones J (2013). "Optimising outcome in congenital hypothyroidism; current opinions on best practice in initial assessment and subsequent management". Journal of Clinical Research in Pediatric Endocrinology (Review). 5 Suppl 1 (4): 13–22. doi:10.4274/jcrpe.849. PMC 3608009. PMID 23154163.
- ^ Maia AL, Goemann IM, Meyer EL, Wajner SM (June 2011). "Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease". The Journal of Endocrinology. 209 (3): 283–97. doi:10.1530/JOE-10-0481. PMID 21415143.
- ^ a b Cheng SY, Leonard JL, Davis PJ (April 2010). "Molecular aspects of thyroid hormone actions". Endocrine Reviews. 31 (2): 139–70. doi:10.1210/er.2009-0007. PMC 2852208. PMID 20051527.
- ^ a b c d Casis O, Echeazarra L, Gallego M (2024). "Deciphering the roles of triiodothyronine (T3) and thyroid-stimulating hormone (TSH) on cardiac electrical remodeling in clinical and experimental hypothyroidism". Journal of Physiology and Biochemistry. 80 (1): 1–9. doi:10.1007/s13105-023-01000-z. PMC 10808292. PMID 38019451.
- ^ a b c d e f g h i Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W (October 2011). "Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum". Thyroid. 21 (10): 1081–125. doi:10.1089/thy.2011.0087. PMC 3472679. PMID 21787128.
- ^ a b c d So M, MacIsaac RJ, Grossmann M (August 2012). "Hypothyroidism" (PDF). Australian Family Physician. 41 (8): 556–62. PMID 23145394.
- ^ Pantalone KM, Hatipoglu BA (December 2014). "Hyponatremia and the Thyroid: Causality or Association?". Journal of Clinical Medicine. 4 (1): 32–6. doi:10.3390/jcm4010032. PMC 4470237. PMID 26237016.
- ^ a b Dons RF, Wians FH Jr (2009). Endocrine and metabolic disorders clinical lab testing manual (4th ed.). Boca Raton: CRC Press. p. 10. ISBN 978-1-4200-7936-4.
- ^ a b c d e Peeters RP (29 June 2017). "Subclinical Hypothyroidism". New England Journal of Medicine. 376 (26): 2556–2565. doi:10.1056/NEJMcp1611144. PMID 28657873. S2CID 56184355.
- ^ a b c Bona G, Prodam F, Monzani A (2013). "Subclinical hypothyroidism in children: natural history and when to treat". Journal of Clinical Research in Pediatric Endocrinology (Review). 5 Suppl 1 (4): 23–8. doi:10.4274/jcrpe.851. PMC 3608012. PMID 23154159.
- ^ a b c Fatourechi V (2009). "Subclinical hypothyroidism: an update for primary care physicians". Mayo Clinic Proceedings (Review). 84 (1): 65–71. doi:10.4065/84.1.65. PMC 2664572. PMID 19121255.
- ^ Baumgartner C, Blum MR, Rodondi N (December 2014). "Subclinical hypothyroidism: summary of evidence in 2014". Swiss Medical Weekly (Review). 144: w14058. doi:10.4414/smw.2014.14058. PMID 25536449.
- ^ Negro R, Stagnaro-Green A (October 2014). "Diagnosis and management of subclinical hypothyroidism in pregnancy". BMJ. 349 (10) g4929. doi:10.1136/bmj.g4929. PMID 25288580. S2CID 21104809.
- ^ Practice Committee of the American Society for Reproductive Medicine (November 2012). "Evaluation and treatment of recurrent pregnancy loss: a committee opinion". Fertility and Sterility. 98 (5): 1103–11. doi:10.1016/j.fertnstert.2012.06.048. PMID 22835448. S2CID 30527688.
- ^ "Recurrent Miscarriage, Investigation and Treatment of Couples". Royal College of Obstetricians & Gynaecologists.
- ^ a b c d Charlton K, Skeaff S (November 2011). "Iodine fortification: why, when, what, how, and who?". Current Opinion in Clinical Nutrition and Metabolic Care. 14 (6): 618–24. doi:10.1097/MCO.0b013e32834b2b30. PMID 21892078. S2CID 22906831.
- ^ World Health Organization, UNICEF, ICCIDD (2008). Assessment of iodine deficiency disorders and monitoring their elimination (PDF) (3rd ed.). Geneva: World Health Organization. ISBN 978-92-4-159582-7. Archived (PDF) from the original on 2013-12-28.
- ^ e-Library of Evidence for Nutrition Actions (eLENA) (2014). "Iodine supplementation during pregnancy". World Health Organization. Archived from the original on 6 March 2014. Retrieved 5 March 2014.
- ^ "Reaching Optimal Iodine Nutrition in Pregnant and Lactating Women and Young Children" (PDF). Joint Statement by the World Health Organization and United Nations Children's Fund. World Health Organization. 2007. Archived from the original (PDF) on 6 March 2014. Retrieved 5 March 2014.
- ^ Becker DV, Braverman LE, Delange F, Dunn JT, Franklyn JA, Hollowell JG, Lamm SH, Mitchell ML, Pearce E, Robbins J, Rovet JF (October 2006). "Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association". Thyroid. 16 (10): 949–51. doi:10.1089/thy.2006.16.949. PMID 17042677. S2CID 28515565.
- ^ Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK (June 2006). "Update of newborn screening and therapy for congenital hypothyroidism". Pediatrics. 117 (6): 2290–303. doi:10.1542/peds.2006-0915. PMID 16740880. S2CID 1068578.
- ^ Pollitt RJ (June 2009). "Newborn blood spot screening: new opportunities, old problems". Journal of Inherited Metabolic Disease. 32 (3): 395–9. doi:10.1007/s10545-009-9962-0. PMID 19412659. S2CID 41563580.
- ^ LeFevre ML (May 2015). "Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 162 (9): 641–50. doi:10.7326/M15-0483. PMID 25798805. S2CID 262490923.
- ^ a b Malt EA, Dahl RC, Haugsand TM, Ulvestad IH, Emilsen NM, Hansen B, Cardenas YE, Skøld RO, Thorsen AT, Davidsen EM (February 2013). "Health and disease in adults with Down syndrome". Tidsskrift for den Norske Laegeforening. 133 (3): 290–4. doi:10.4045/tidsskr.12.0390. PMID 23381164.
- ^ "Coeliac disease: recognition, assessment and management". www.nice.org.uk. National Institute for Health and Care Excellence. 2 September 2015. Retrieved 9 March 2021.
- ^ McAninch EA, Rajan KB, Miller CH, Bianco AC (1 December 2018). "Systemic Thyroid Hormone Status During Levothyroxine Therapy In Hypothyroidism: A Systematic Review and Meta-Analysis". The Journal of Clinical Endocrinology & Metabolism. 103 (12): 4533–4542. doi:10.1210/jc.2018-01361. PMC 6226605. PMID 30124904.
- ^ Cascorbi I (August 2012). "Drug interactions--principles, examples, and clinical consequences". Deutsches Ärzteblatt International (Review). 109 (33–34): 546–55, quiz 556. doi:10.3238/arztebl.2012.0546. PMC 3444856. PMID 23152742.
- ^ Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G (August 2005). "REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine". The Journal of Clinical Endocrinology and Metabolism (Review). 90 (8): 4946–54. doi:10.1210/jc.2005-0184. hdl:10261/24668. PMID 15928247.
- ^ a b British Thyroid Association Executive Committee (November 2007). "Armour Thyroid(USP) and combinedthyroxine/tri-iodothyronine as thyroid hormone replacement" (PDF). British Thyroid Association. Archived from the original (PDF) on 3 December 2008. Retrieved 25 December 2013.
- ^ a b Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP (July 2012). "2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism". European Thyroid Journal. 1 (2): 55–71. doi:10.1159/000339444. PMC 3821467. PMID 24782999.
- ^ a b Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM (12 December 2014). "Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement". Thyroid. 24 (12): 1670–1751. doi:10.1089/thy.2014.0028. ISSN 1050-7256. PMC 4267409. PMID 25266247.
- ^ Ebling PR (2011). "ESA Position Statement on Desiccated Thyroid or Thyroid Extract" (PDF). Endocrine Society of Australia. Archived from the original (PDF) on 26 January 2014. Retrieved 13 December 2013.
- ^ a b Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Singh Ospina N, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M (14 May 2019). "Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline". BMJ. 365 l2006. doi:10.1136/bmj.l2006. PMID 31088853.
- ^ Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N (June 2008). "Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality". Annals of Internal Medicine (Meta-analysis). 148 (11): 832–45. doi:10.7326/0003-4819-148-11-200806030-00225. PMID 18490668.
- ^ Müller P, Leow MK, Dietrich JW (2022). "Minor perturbations of thyroid homeostasis and major cardiovascular endpoints-Physiological mechanisms and clinical evidence". Frontiers in Cardiovascular Medicine. 9 942971. doi:10.3389/fcvm.2022.942971. PMC 9420854. PMID 36046184.
- ^ Villar HC, Saconato H, Valente O, Atallah AN (July 2007). "Thyroid hormone replacement for subclinical hypothyroidism". The Cochrane Database of Systematic Reviews. 2009 (3) CD003419. doi:10.1002/14651858.CD003419.pub2. PMC 6610974. PMID 17636722.
- ^ Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Jüni P, Aujesky D, Rodondi N (May 2015). "Subclinical thyroid dysfunction and fracture risk: a meta-analysis". JAMA. 313 (20): 2055–65. doi:10.1001/jama.2015.5161. PMC 4729304. PMID 26010634.
- ^ Rieben C, Segna D, da Costa BR, Collet TH, Chaker L, Aubert CE, Baumgartner C, Almeida OP, Hogervorst E, Trompet S, Masaki K, Mooijaart SP, Gussekloo J, Peeters RP, Bauer DC, Aujesky D, Rodondi N (December 2016). "Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies". The Journal of Clinical Endocrinology and Metabolism. 101 (12): 4945–4954. doi:10.1210/jc.2016-2129. PMC 6287525. PMID 27689250.
- ^ a b Wiles KS, Jarvis S, Nelson-Piercy C (October 2015). "Are we overtreating subclinical hypothyroidism in pregnancy?". BMJ. 351 h4726. doi:10.1136/bmj.h4726. PMID 26459315. S2CID 32615623.
- ^ Reid SM, Middleton P, Cossich MC, Crowther CA, Bain E (May 2013). Reid SM (ed.). "Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy". The Cochrane Database of Systematic Reviews. 2013 (5) CD007752. doi:10.1002/14651858.CD007752.pub3. PMC 11664309. PMID 23728666.
- ^ Pearce EN (1 July 2022). "Management of Hypothyroidism and Hypothyroxinemia During Pregnancy". Endocrine Practice. 28 (7): 711–718. doi:10.1016/j.eprac.2022.05.004. ISSN 1530-891X. PMID 35569735.
- ^ Provinciatto H, Moreira MV, Neves GR, De Freitas LR, Mitsui HC, Zhang JM, Araujo Júnior E (1 June 2024). "Levothyroxine for subclinical hypothyroidism during pregnancy: an updated systematic review and meta-analysis of randomized controlled trials". Archives of Gynecology and Obstetrics. 309 (6): 2387–2393. doi:10.1007/s00404-024-07512-3. ISSN 1432-0711. PMID 38676741.
- ^ Sankoda A, Suzuki H, Imaizumi M, Yoshihara A, Kobayashi S, Katai M, Hamada K, Hidaka Y, Yoshihara A, Nakamura H, Kubota S, Kakita-Kobayashi M, Iwase A, Sugiyama T, Ota E (18 February 2024). "Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Thyroid. 34 (4): 519–530. doi:10.1089/thy.2023.0546. ISSN 1557-9077. PMID 38368537.
- ^ Ke Lq, Hu Y, Yang K, Tong N (12 February 2015). "Chinese herbal medicines for hypothyroidism". Cochrane Database of Systematic Reviews. 2015 (2) CD008779. doi:10.1002/14651858.CD008779.pub2. PMC 10625441. PMID 25914906.
- ^ Gottwald-Hostalek U, Schulte B (January 2022). "Low awareness and under-diagnosis of hypothyroidism". Current Medical Research and Opinion. 38 (1): 59–64. doi:10.1080/03007995.2021.1997258. PMID 34698615. S2CID 239888323.
- ^ Monzani A, Prodam F, Rapa A, Moia S, Agarla V, Bellone S, Bona G (January 2013). "Endocrine disorders in childhood and adolescence. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review". European Journal of Endocrinology. 168 (1): R1 – R11. doi:10.1530/EJE-12-0656. PMID 22989466.
- ^ a b Leung AM, Braverman LE, Pearce EN (November 2012). "History of U.S. iodine fortification and supplementation". Nutrients. 4 (11): 1740–6. doi:10.3390/nu4111740. PMC 3509517. PMID 23201844.
- ^ a b c d e f g h McAninch EA, Bianco AC (January 2016). "The History and Future of Treatment of Hypothyroidism". Annals of Internal Medicine. 164 (1): 50–6. doi:10.7326/M15-1799. PMC 4980994. PMID 26747302.
- ^ Murray GR (October 1891). "Note on the Treatment of Myxoedema by Hypodermic Injections of an Extract of the Thyroid Gland of a Sheep". British Medical Journal. 2 (1606): 796–7. doi:10.1136/bmj.2.1606.796. PMC 2273741. PMID 20753415.
- ^ Fox EL (October 1892). "A Case of Myxoedema Treated by Taking Extract of Thyroid by the Mouth". British Medical Journal. 2 (1661): 941. doi:10.1136/bmj.2.1661.941. PMC 2421284. PMID 20753901.
- ^ a b c d Mooney CT (May 2011). "Canine hypothyroidism: a review of aetiology and diagnosis". New Zealand Veterinary Journal. 59 (3): 105–14. doi:10.1080/00480169.2011.563729. PMID 21541883. S2CID 29535272.
External links
[edit]- "Hypothyroidism information for patients". American Thyroid Association.
Hypothyroidism
View on GrokipediaOverview
Definition
Hypothyroidism is a medical condition characterized by insufficient production of thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), by the thyroid gland.[3] This underactive state leads to a slowdown in the body's metabolic processes, affecting energy utilization and overall physiological function.[2] The thyroid gland, located in the neck, normally synthesizes these hormones through iodination of tyrosine residues in thyroglobulin, a process regulated by thyroid-stimulating hormone (TSH) from the pituitary gland.[6] Thyroid hormones play a critical role in regulating basal metabolic rate, which governs the consumption of oxygen and production of heat in cells throughout the body.[7] They are essential for promoting growth and development, particularly during fetal and early childhood stages, by influencing cell differentiation, proliferation, and maturation in various tissues.[8] Additionally, T3 and T4 support organ function, including cardiovascular, nervous, and musculoskeletal systems, ensuring normal homeostasis in adults.[6] In contrast to hyperthyroidism, where the thyroid overproduces hormones leading to accelerated metabolism, hypothyroidism results in hormone deficiency and metabolic deceleration.[9] Euthyroid states represent normal thyroid function with balanced hormone levels.[6] Hypothyroidism can manifest as congenital, present at birth due to developmental defects, or acquired later in life from various insults to the gland.[10]Classification
Hypothyroidism is classified primarily based on its etiology, distinguishing between dysfunction originating in the thyroid gland itself and issues arising from the central regulation of thyroid hormone production. Primary hypothyroidism results from failure of the thyroid gland to produce sufficient thyroid hormones, often due to autoimmune destruction as seen in Hashimoto's thyroiditis, the most common cause in iodine-sufficient regions. In contrast, central hypothyroidism encompasses secondary forms caused by pituitary gland insufficiency, leading to inadequate thyroid-stimulating hormone (TSH) secretion, and tertiary forms stemming from hypothalamic dysfunction that impairs thyrotropin-releasing hormone (TRH) production.[11][12][13] The condition is further subdivided by severity and biochemical profile, with overt hypothyroidism defined by elevated TSH levels alongside low free thyroxine (T4) concentrations, typically resulting in noticeable clinical symptoms. Subclinical hypothyroidism, a milder variant, features elevated TSH with normal T4 levels and is often asymptomatic or presents with subtle manifestations. Severity can be graded as mild (corresponding to subclinical cases), moderate (overt hypothyroidism with TSH often exceeding 10 mU/L), and severe (progressing to myxedema coma, a life-threatening decompensation involving hypothermia, altered mental status, and multiorgan failure).[11][14][15] Hypothyroidism is also categorized temporally as congenital, present at birth due to factors such as thyroid dysgenesis or maternal iodine deficiency, which requires early screening to prevent developmental delays, or acquired, developing later in life from causes like autoimmune disease, surgical intervention, or radiation therapy. These classifications provide a framework for understanding the diverse presentations and guide appropriate management strategies.[12][13][11]Clinical Presentation
Signs and Symptoms in Adults
Hypothyroidism in adults often presents with a gradual onset of nonspecific symptoms that can mimic other conditions, making early recognition challenging. Common symptoms include fatigue, which may manifest as hypersomnia, affects daily functioning, is reported in the majority of cases, and can occur even in subclinical hypothyroidism, contributing to stress intolerance and slower recovery from illness. Persistent fatigue is a primary and often debilitating symptom of hypothyroidism. It is frequently exacerbated by concurrent deficiencies in vitamin D and vitamin B12, which are common in patients with autoimmune thyroid disease. Studies have reported vitamin B12 deficiency in approximately 46% of patients with autoimmune hypothyroidism, while vitamin D deficiency has been observed in up to 96% in some cohorts. These deficiencies share overlapping symptoms with hypothyroidism, including fatigue, weakness, depression, and cognitive impairment, and can worsen persistent symptoms. Screening for these deficiencies is often recommended in hypothyroid patients.[16] Patients also experience unexplained weight gain despite often reduced appetite and no significant changes in diet or activity levels.[3][1][17][18][5] Patients frequently experience cold intolerance, which is typically a generalized increased sensitivity to cold even in warm environments comfortable to others, due to slowed metabolism and reduced thermogenesis from thyroid hormone deficiency. Cold intolerance is generally systemic rather than localized; a specific intense chilling sensation confined to the head is not described as a typical symptom in major medical sources. Patients also experience constipation due to slowed gastrointestinal motility.[3][11] Dry skin and hair loss, including thinning of the outer eyebrows, are dermatological manifestations, while menstrual irregularities such as heavier or irregular periods occur in women of reproductive age.[3][1] Depression, anxiety, occasional obsessions, and cognitive issues, like memory problems and occasional headaches, further contribute to the emotional and mental burden.[3][11][19] Physical signs are equally indicative and include bradycardia (low heart rate), diastolic hypertension (particularly elevated diastolic pressure due to increased vascular resistance), although hypotension may occur in severe cases, a slowed heart rate that reflects reduced metabolic demands, and goiter, an enlarged thyroid gland palpable in the neck.[3][11][20] Delayed relaxation of deep tendon reflexes, particularly noticeable in the ankles, is a classic neurological sign stemming from diminished muscle responsiveness; headaches are occasionally reported and rarely associated with increased intracranial pressure.[11][21] Hoarseness arises from vocal cord edema, and periorbital edema contributes to a puffy facial appearance.[3][11] Patients may also experience a sensation of excessive mucus in the throat (often described as a "phlegmy" or "verschleimter Hals"), which can be linked to hoarseness, swallowing difficulties, or sinus/nasal congestion from fluid retention, myxedematous changes, edema, and hypertrophy of mucous glands in the upper airways.[11][22] Hypothyroidism may also be associated with nasal congestion or obstruction resembling nonallergic rhinitis, attributed to myxedematous changes such as fluid retention, edema in nasal tissues, hypertrophy of mucous glands, and accumulation of glycosaminoglycans leading to swelling; these nasal symptoms often improve with levothyroxine treatment.[23] Additionally, hypothyroidism is associated with obstructive sleep apnea, which can contribute to breathing difficulties, including positional worsening due to upper airway obstruction from myxedema-related tissue swelling.[22] The condition's progression is typically insidious, with symptoms evolving over months to years from subtle complaints like mild fatigue to more pronounced effects as thyroid hormone levels decline further.[3][1] Systemically, hypothyroidism impacts the cardiovascular system by causing dyslipidemia characterized by elevated low-density lipoprotein (LDL) cholesterol and triglyceride levels, frequently with normal high-density lipoprotein (HDL) cholesterol levels, increasing the risk of atherosclerosis and heart disease.[3][24][20] These cardiovascular manifestations and lipid abnormalities are commonly associated with hypothyroidism but are nonspecific and not definitive for diagnosis; thyroid function tests (e.g., TSH and free T4) are required for confirmation. Musculoskeletal involvement manifests as myalgias, including muscle aches, tenderness, stiffness, weakness, and joint pain (which may include lower back pain), which can limit mobility.[1][11][25] Bladder pressure and frequent urination are not typical symptoms of hypothyroidism; however, some evidence links hypothyroidism to urinary retention or reduced voiding rather than increased frequency.[26] Cognitively, it exacerbates depressive symptoms and impairs memory and concentration, potentially leading to pseudodementia in severe cases.[3][11] In rare untreated instances, symptoms can culminate in myxedema coma, a life-threatening emergency characterized by profound lethargy and hypothermia.[3][1]Effects in Pregnancy
During pregnancy, the demand for thyroid hormones increases by approximately 50% due to physiological adaptations such as elevated renal clearance of iodide and stimulation of the thyroid gland by human chorionic gonadotropin (hCG), which can unmask subclinical hypothyroidism in susceptible women.[27] This heightened requirement, combined with the placenta's role in metabolizing maternal thyroxine (T4), places additional stress on thyroid function, potentially leading to overt hypothyroidism if iodine intake is marginal or preexisting thyroid autoimmunity is present.[28] Maternal hypothyroidism is associated with several adverse outcomes, including an increased risk of preeclampsia, anemia, and postpartum hemorrhage. Untreated overt hypothyroidism elevates the odds of preeclampsia through mechanisms involving endothelial dysfunction and placental insufficiency, while anemia may arise from impaired erythropoiesis due to thyroid hormone deficiency.[27] Postpartum hemorrhage risk is heightened, particularly in cases of severe hypothyroidism, due to reduced uterine contractility and coagulopathy.[28] Fetal risks from maternal hypothyroidism include neurodevelopmental delays, low birth weight, higher rates of miscarriage, and stillbirth. Insufficient transplacental transfer of maternal T4 in early gestation can impair fetal brain development, leading to decrements in IQ and psychomotor skills, as evidenced by cohort studies showing persistent cognitive deficits in offspring.[27] Low birth weight and preterm delivery are common, often linked to placental abruption or intrauterine growth restriction, while miscarriage and stillbirth rates increase significantly in untreated cases, with odds ratios up to 2-4 times higher compared to euthyroid pregnancies.[28] Symptoms of hypothyroidism during pregnancy often overlap with normal gestational changes, such as fatigue and weight gain, which can delay recognition, but specific indicators like persistent nausea, constipation beyond typical levels, or cold intolerance may prompt further evaluation.[27] These overlaps underscore the importance of routine thyroid screening, as diagnosis relies on laboratory tests detailed elsewhere.[28]Manifestations in Children
Hypothyroidism in children presents with age-specific manifestations that differ from those in adults, primarily affecting growth, development, and metabolism. In neonates and infants with congenital hypothyroidism, common signs include prolonged jaundice, hypotonia (poor muscle tone), large fontanelles (soft spots on the skull), and umbilical hernia.[29][3] Additional features may involve feeding difficulties, such as poor sucking or choking episodes, constipation, hoarse cry, puffy face, macroglossia (enlarged tongue), and dry skin.[29][30] These subtle signs can be overlooked without newborn screening, which enables early detection and intervention to prevent severe outcomes.[29] If congenital hypothyroidism remains untreated, it leads to cretinism, characterized by profound intellectual disability, stunted physical growth, and developmental delays in motor skills and cognition.[31][32] In older infants, manifestations may include lethargy, hypothermia, and delayed bone maturation, such as absent epiphyses in the knees on radiographs.[30] Acquired hypothyroidism, which develops after the neonatal period, often manifests as growth retardation and short stature due to slowed linear growth velocity.[33][30] Other symptoms include fatigue, constipation, cold intolerance, dry skin, brittle hair, and muscle weakness or aches.[33] In school-age children, poor school performance may arise from concentration difficulties and sluggishness, while dental development is delayed, leading to late eruption of permanent teeth.[3][30] Adolescents commonly experience delayed puberty, with girls showing amenorrhea or irregular menses and boys exhibiting underdeveloped secondary sexual characteristics.[33][3] Age-related differences are notable: infants primarily show feeding issues and constipation alongside hypotonia, whereas school-age children exhibit prominent short stature and fatigue impacting daily activities.[3][33] In severe or prolonged cases across pediatric ages, manifestations can include relative overweight despite poor appetite, goiter, and rare syndromes like Kocher-Debre-Semelaigne, featuring muscular hypertrophy and pseudohypertrophy.[30] Long-term effects of untreated hypothyroidism in children encompass delayed bone maturation, resulting in persistent short stature and skeletal abnormalities, as well as impaired intellectual development with risks of subtle cognitive deficits even after treatment initiation.[30][34] Early thyroid hormone replacement mitigates these risks, but delays can lead to irreversible growth failure and neurodevelopmental issues.[32][30]Myxedema Coma
Myxedema coma represents a rare and life-threatening decompensation of severe, long-standing hypothyroidism, characterized by profound metabolic and multisystem dysfunction that requires immediate intensive care intervention. This endocrine emergency typically occurs in patients with inadequately treated or undiagnosed hypothyroidism, leading to critically low levels of thyroid hormones and elevated thyroid-stimulating hormone. It manifests as a hypometabolic state with hallmark features including hypothermia, altered mental status ranging from lethargy to coma, hypotension, hyponatremia, bradycardia, and hypoglycemia, often progressing rapidly to multiorgan failure if untreated. The condition predominantly affects older adults, particularly women over 60 years, with an estimated incidence of approximately 0.12 cases per million population annually.[35][11][36] Common precipitants in susceptible hypothyroid patients include infections such as pneumonia or urinary tract infections, exposure to cold environments, surgical procedures, and administration of sedatives, anesthetics, or other drugs that depress central nervous system function. Other triggers encompass trauma, cerebrovascular events, congestive heart failure, and abrupt discontinuation of thyroid hormone replacement therapy, with these factors often unmasking the underlying thyroid deficiency in winter months when incidence peaks. In over 77% of cases, such stressors precipitate the coma in individuals with preexisting primary hypothyroidism, which accounts for more than 95% of occurrences.[35][37][38] Pathognomonic clinical signs include non-pitting edema known as myxedema, resulting in doughy, swollen skin, particularly around the eyes and extremities, alongside serous effusions such as pericardial or pleural accumulations that contribute to hemodynamic instability. Respiratory failure is frequent, stemming from hypoventilation, diaphragmatic muscle weakness, or upper airway obstruction due to myxedema-related swelling, including macroglossia and laryngeal edema. Additional features encompass seizures, cardiogenic shock, and fluid retention, with hypothermia present in about 72% of patients, bradycardia in 66%, and altered mental status in nearly 89%. These signs underscore the rapid deterioration and multisystem involvement unique to this extreme hypothyroid state.[36][35][11] Despite advances in recognition and management, myxedema coma carries a high mortality rate of approximately 39%, ranging up to 60% in severe cases, primarily due to shock, multiple organ failure, and delays in diagnosis. Even with prompt supportive care, outcomes remain poor, influenced by patient age, comorbidities, and the presence of precipitants, highlighting its status as one of the most lethal endocrine emergencies.[35][36][11]Etiology
Primary Hypothyroidism
Primary hypothyroidism refers to thyroid gland dysfunction that directly impairs the synthesis and secretion of thyroid hormones, independent of pituitary or hypothalamic regulation. This condition accounts for the majority of hypothyroidism cases and arises from various intrinsic thyroid pathologies. In iodine-sufficient areas, autoimmune destruction dominates, while iodine deficiency prevails globally in resource-limited regions. The most common cause in developed countries is autoimmune thyroiditis, with Hashimoto's thyroiditis being the predominant form, characterized by lymphocytic infiltration and progressive glandular fibrosis leading to reduced hormone output.[11] This disorder affects women up to seven times more frequently than men and often coexists with other autoimmune conditions like type 1 diabetes or celiac disease.[5] Atrophic thyroiditis, a variant of autoimmune thyroiditis, involves chronic inflammation resulting in thyroid atrophy and dense fibrosis without prominent goiter, further contributing to hormone deficiency.[2] Iodine deficiency stands as the primary global etiology, particularly in developing regions where soil and dietary iodine levels are low, leading to impaired thyroid hormone synthesis and endemic goiter.[11] This preventable cause affects millions, though public health measures like iodized salt have significantly reduced its incidence in many areas.[3] Iatrogenic factors frequently result from therapeutic interventions targeting thyroid or adjacent structures. Thyroidectomy, the surgical removal of all or part of the gland for conditions such as cancer or multinodular goiter, inevitably causes hypothyroidism requiring hormone replacement.[2] Radioactive iodine ablation, commonly used for hyperthyroidism like Graves' disease or thyroid malignancy, destroys functional thyroid tissue and induces permanent hypothyroidism in 80% to 90% of patients within 8 to 20 weeks.[11] Similarly, external radiation therapy to the head or neck, often for lymphomas or other cancers, damages thyroid follicles and elevates hypothyroidism risk over time.[5] Drug-induced hypothyroidism occurs when medications interfere with thyroid hormone production or release, particularly in susceptible individuals. Lithium, a mainstay in bipolar disorder treatment, inhibits thyroid hormone secretion and can precipitate hypothyroidism in up to 20% of long-term users.[2] Amiodarone, an iodine-rich antiarrhythmic agent, disrupts hormone synthesis through excess iodine load or direct toxicity, affecting 5% to 20% of recipients.[5] Interferon-alpha, used in hepatitis or malignancy therapy, may trigger autoimmune thyroiditis or directly suppress glandular function.[3] Infiltrative disorders, though uncommon, involve pathological deposits that compromise thyroid architecture. Amyloidosis leads to amyloid protein accumulation within the gland, impairing hormone production, while sarcoidosis causes granulomatous infiltration that disrupts follicular cells and vascular supply.[5] These rare etiologies often manifest in the context of systemic disease and require targeted management of the underlying condition.Central Hypothyroidism
Central hypothyroidism arises from dysfunction in the hypothalamic-pituitary-thyroid axis, specifically involving the pituitary gland (secondary hypothyroidism) or the hypothalamus (tertiary hypothyroidism), leading to inadequate stimulation of the thyroid gland despite its intrinsic normalcy.[39] Unlike primary forms, central hypothyroidism is characterized by low or inappropriately normal thyroid-stimulating hormone (TSH) levels in the presence of low free thyroxine (FT4).[40] Secondary central hypothyroidism results primarily from pituitary gland disorders that impair TSH production or secretion. Common causes include pituitary adenomas, which are benign tumors that can compress normal pituitary tissue, and craniopharyngiomas, often seen in children and arising from remnants of Rathke's pouch.[39] Sheehan's syndrome, a postpartum pituitary necrosis due to severe hemorrhage and hypovolemic shock, leads to panhypopituitarism including TSH deficiency.[39] Traumatic brain injury or pituitary surgery can also damage the pituitary, resulting in secondary hypothyroidism.[41] Tertiary central hypothyroidism stems from hypothalamic dysfunction, reducing thyrotropin-releasing hormone (TRH) production or release, which in turn diminishes pituitary TSH secretion. Hypothalamic tumors, such as gliomas or hamartomas, can disrupt this axis, as can infiltrative diseases like sarcoidosis or histiocytosis.[39] Rare genetic mutations contribute, including defects in the TSH-beta gene (TSHB), causing isolated TSH deficiency and congenital nongoitrous hypothyroidism, and mutations in the TRH gene or its receptor (TRHR), leading to TRH deficiency or resistance.[39] Central hypothyroidism frequently occurs within the broader context of hypopituitarism, where multiple pituitary hormones are deficient, increasing risks for associated conditions such as adrenal insufficiency from adrenocorticotropic hormone (ACTH) shortfall and infertility due to gonadotropin (FSH/LH) deficiencies.[42] Adrenal insufficiency can precipitate life-threatening crises if thyroid replacement is initiated without concurrent glucocorticoid support.[43] Recent advances emphasize genetic etiologies, particularly in congenital cases, with mutations in the PROP1 gene being the most common cause of multiple pituitary hormone deficiency (MPHD), often presenting with central hypothyroidism alongside growth hormone and gonadotropin deficits. The 2018 European Thyroid Association (ETA) guidelines highlight the role of molecular diagnosis in identifying such mutations to guide targeted management.[44]Pathophysiology
Thyroid Hormone Synthesis and Regulation
Thyroid hormone synthesis occurs primarily in the follicular cells of the thyroid gland. Iodide, obtained from dietary sources, is actively transported into thyrocytes via the sodium-iodide symporter (NIS) located on the basolateral membrane, achieving intracellular concentrations 20 to 50 times higher than in plasma; this process is energy-dependent and stimulated by thyroid-stimulating hormone (TSH).[45] Once inside the cell, iodide diffuses to the apical membrane and is oxidized to reactive iodine by thyroid peroxidase (TPO) in the presence of hydrogen peroxide (H₂O₂) generated by dual oxidases (DUOX).[45] The oxidized iodine then iodinates tyrosine residues on thyroglobulin (Tg), a large glycoprotein stored in the follicular lumen, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT).[45] TPO subsequently catalyzes the coupling of these iodotyrosines: two DIT molecules couple to form thyroxine (T4), while one DIT and one MIT couple to form triiodothyronine (T3).[45] The iodinated Tg is endocytosed, proteolytically cleaved by lysosomal enzymes such as cathepsins to release T4 and T3, and the hormones are secreted into the bloodstream; MIT and DIT are deiodinated intracellularly for iodine recycling.[45] In euthyroid adults, the thyroid gland produces approximately 94–110 μg of T4 and 4–8 μg of T3 daily.[46] Regulation of thyroid hormone production is governed by the hypothalamic-pituitary-thyroid (HPT) axis. Thyrotropin-releasing hormone (TRH) is secreted by neurons in the paraventricular nucleus of the hypothalamus and travels via the hypophyseal portal system to stimulate the anterior pituitary gland to release TSH.[6] TSH binds to G-protein-coupled receptors on thyroid follicular cells, activating adenylate cyclase and the phospholipase C pathway, which upregulates NIS expression, TPO activity, and Tg synthesis to promote iodide uptake, organification, and hormone release.[6] Circulating free T3 and T4 exert negative feedback on the hypothalamus and pituitary, inhibiting TRH and TSH secretion to maintain homeostasis; this feedback primarily targets free hormone levels rather than total concentrations.[6] Although the thyroid secretes mostly T4 (about 80% of output) with smaller amounts of T3, the biologically active form T3 is predominantly generated peripherally through deiodination of T4.[6] This conversion occurs via outer-ring deiodination (ORD) catalyzed by type 1 iodothyronine deiodinase (D1), which is expressed in high-blood-flow tissues like the liver and kidneys and contributes to circulating T3 levels, and type 2 deiodinase (D2), found in the central nervous system, pituitary, brown adipose tissue, and skeletal muscle, which locally regulates tissue-specific T3 availability.[47] Approximately 80% of daily T3 production (~50 nmol) arises from this peripheral pathway, with D1 and D2 accounting for the ORD reaction that removes an iodine atom from the outer ring of T4.[47] In circulation, thyroid hormones are transported bound to plasma proteins to prevent rapid clearance and ensure steady delivery to tissues. Thyroxine-binding globulin (TBG), synthesized in the liver, is the primary carrier, binding about 75% of serum T4 and a similar proportion of T3 with high affinity (association constant of 1 × 10¹⁰ M⁻¹ for T4).[48] Transthyretin and albumin serve as secondary binders, transporting the remainder, while only 0.03% of T4 and 0.3% of T3 circulate in their free, biologically active forms.[48] TBG's half-life is approximately 5 days, and its concentration (1.1–2.1 mg/dL) supports a large extrathyroidal hormone pool, buffering daily fluctuations in secretion.[48]Consequences of Hormone Deficiency
Hypothyroidism leads to a profound metabolic slowdown primarily through the deficiency of thyroid hormones, which are essential regulators of energy expenditure. The basal metabolic rate decreases by approximately 30-40% in overt hypothyroidism due to reduced mitochondrial activity and impaired expression of genes involved in oxidative phosphorylation.[8] This hypometabolic state manifests as diminished thermogenesis, where thyroid hormone normally activates uncoupling proteins in brown adipose tissue to generate heat; in its absence, heat production is curtailed, contributing to generalized cold intolerance—an increased sensitivity to cold temperatures affecting the entire body—rather than localized sensations such as intense chilling confined to the head, which is not a characteristic manifestation of hypothyroidism according to standard medical literature.[49][3][11] Furthermore, lipid metabolism is disrupted, with slowed triglyceride clearance and increased hepatic synthesis leading to accumulation of lipids in tissues, including the liver, exacerbating dyslipidemia.[50] In the cardiovascular system, thyroid hormone deficiency impairs myocardial function by downregulating sarcomeric proteins and calcium-handling genes, resulting in decreased cardiac contractility and stroke volume.[20] This reduction in cardiac output is compounded by increased systemic vascular resistance due to endothelial dysfunction and heightened sensitivity to catecholamines, promoting diastolic hypertension while systolic pressure remains relatively preserved.[51] Lipid abnormalities further contribute, as hypothyroidism elevates low-density lipoprotein (LDL) cholesterol levels through decreased LDL receptor activity in the liver and reduced clearance from circulation, fostering atherosclerosis and endothelial damage.[52] These hemodynamic and metabolic changes collectively heighten the risk of ischemic heart disease.[53] Neurologically, the lack of thyroid hormones affects brain metabolism and structure, leading to cognitive impairment via reduced cerebral glucose utilization and altered neurotransmitter synthesis, such as decreased serotonin and dopamine activity in key regions like the hippocampus.[54] Chronic deficiency can also promote demyelination in peripheral nerves through impaired Schwann cell function and axonal transport, resulting in neuropathy characterized by slowed nerve conduction.[55] In severe cases, prolonged hypothyroidism overwhelms adaptive mechanisms, culminating in myxedema coma, where profound hypothermia, hyponatremia, and cerebral edema arise from multisystem failure, including respiratory depression and cardiovascular collapse.[56] In congenital hypothyroidism, hormone deficiency impairs growth and development, leading to delayed linear growth and bone maturation due to reduced chondrocyte proliferation in growth plates, as well as neurocognitive deficits from disrupted neuronal migration, myelination, and synaptic plasticity in the developing brain.[57] Emerging research highlights genetic factors influencing the severity of hormone deficiency consequences, particularly polymorphisms in deiodinase genes like DIO2. The Thr92Ala variant in DIO2, for instance, reduces the enzyme's efficiency in converting thyroxine to active triiodothyronine at the tissue level, leading to suboptimal local thyroid hormone action and more persistent symptoms such as fatigue and cognitive deficits even in euthyroid states.[58] Studies from 2023-2025 indicate that such polymorphisms may explain inter-individual variability in symptom severity among hypothyroid patients on standard levothyroxine therapy. These findings underscore the role of pharmacogenomics in tailoring treatment to mitigate deficiency impacts.[59]Diagnostic Evaluation
Laboratory Tests
The diagnosis of hypothyroidism relies primarily on blood tests measuring thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels, which provide confirmation of thyroid hormone deficiency.[60][61] TSH serves as the first-line screening test, with elevated levels (>4.5 mU/L) indicating primary hypothyroidism due to thyroid gland failure, while low or inappropriately normal TSH alongside low FT4 suggests central hypothyroidism from pituitary or hypothalamic dysfunction.[5][62] In overt hypothyroidism, FT4 levels are low, confirming the diagnosis when paired with elevated TSH; in subclinical hypothyroidism, FT4 remains normal despite elevated TSH.[63][61] Additional tests include measurement of anti-thyroid peroxidase (anti-TPO) antibodies to identify autoimmune etiology, such as Hashimoto's thyroiditis, which is present in most cases of primary hypothyroidism. Serum thyroglobulin (Tg) levels may also be elevated in autoimmune hypothyroidism due to inflammation and destruction of thyroid follicular cells, typically occurring alongside elevated TSH and low FT4 (in overt cases) or normal FT4 (in subclinical cases).[64] Total triiodothyronine (T3) levels are rarely needed for initial diagnosis but may be assessed if there is suspicion of impaired peripheral conversion of T4 to T3.[62] Reference ranges for TSH and FT4 are method-specific and should be adjusted for age, sex, and pregnancy; for example, TSH upper limits may increase slightly with age (e.g., up to 7 mU/L in those over 70) and are trimester-specific during pregnancy (e.g., <2.5 mU/L in the first trimester).[65][61] Common pitfalls in interpretation include non-thyroidal illness syndrome (euthyroid sick syndrome), where acute or chronic illness can suppress TSH and alter FT4 levels without true thyroid dysfunction, necessitating repeat testing after recovery.[62][63] Biotin supplements can also interfere with immunoassay results, leading to falsely low TSH or high FT4 readings.[61] Updated 2024 reviews emphasize the combined use of TSH and FT4 assays for accurate diagnosis, incorporating population-specific reference intervals to improve precision across diverse groups.[61][66]Clinical and Imaging Assessment
The clinical assessment of hypothyroidism begins with a thorough history to identify risk factors and symptom chronology. Patients should be queried about family history of thyroid disorders, as autoimmune thyroiditis, the most common cause, has a genetic predisposition. Exposure to neck or head radiation, such as from prior cancer therapy, increases the risk of thyroid damage leading to hypothyroidism. Certain medications, including lithium, amiodarone, and immune checkpoint inhibitors, can impair thyroid function and should be documented. The duration and progression of symptoms, such as fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, and menstrual irregularities, help gauge severity and guide urgency of evaluation.[11][2][67] Physical examination focuses on identifying characteristic signs that support the history. Palpation of the thyroid gland is essential to detect goiter, which may present as diffuse enlargement in autoimmune cases or nodular in iodine deficiency or multinodular goiter; a firm, irregular texture suggests Hashimoto's thyroiditis. Reflexes, particularly the ankle jerk, often show delayed relaxation phase due to slowed metabolism. Skin changes include dryness, coolness, and pallor, while hair may appear coarse, brittle, and thinning, especially in the outer third of the eyebrows. Additional findings like periorbital edema, hoarse voice, and bradycardia contribute to the overall picture. These signs, though nonspecific, have high specificity when combined with elevated TSH levels in primary hypothyroidism.[68][11][67] Imaging modalities complement the clinical findings by evaluating structural abnormalities. Thyroid ultrasound is the preferred initial imaging for assessing goiter or nodules, providing details on gland size, echogenicity (often heterogeneous in autoimmune hypothyroidism), vascularity, and nodule characteristics such as hypoechogenicity or microcalcifications that raise malignancy concern. It is particularly useful when palpation reveals asymmetry or when etiology is unclear. For suspected central hypothyroidism, magnetic resonance imaging (MRI) of the pituitary and hypothalamus is indicated to identify lesions like adenomas, infiltrative diseases, or trauma-related damage that impair TSH secretion. MRI with contrast enhances detection of sellar or parasellar masses. Fine-needle aspiration biopsy is reserved for suspicious nodules identified on ultrasound, such as those with irregular margins or rapid growth, and is rarely needed in uncomplicated hypothyroidism.[69][67][70] Integration of history, physical, and imaging findings enables pattern recognition for etiology. For instance, a family history of autoimmunity with a firm goiter and heterogeneous ultrasound appearance points to primary hypothyroidism from Hashimoto's, while absent goiter, normal thyroid imaging, and pituitary MRI abnormalities suggest central causes. This multifaceted approach refines differential diagnosis and informs targeted management.[62][44]Diagnosis in Special Populations
Central hypothyroidism presents unique diagnostic challenges due to its origin in pituitary or hypothalamic dysfunction, manifesting as low free thyroxine (FT4) levels with low or inappropriately normal thyroid-stimulating hormone (TSH) concentrations. This biochemical profile contrasts with primary hypothyroidism, where TSH is markedly elevated, and requires careful differentiation to avoid misdiagnosis. In patients with suspected pituitary disease, the thyrotropin-releasing hormone (TRH) stimulation test serves as a valuable adjunct, evaluating the pituitary's capacity to secrete TSH in response to TRH administration, particularly when baseline T4 is low. Confirmation often involves imaging of the hypothalamic-pituitary axis alongside these hormonal assessments to identify underlying structural causes. Subclinical hypothyroidism, a milder form of thyroid underactivity, is identified by mildly elevated TSH levels ranging from 4.0 to 10.0 mU/L alongside normal FT4, with persistence confirmed over 3-6 months to exclude transient elevations. Risk stratification is essential and includes testing for thyroid peroxidase antibodies (TPOAb) to detect autoimmune predisposition, as positive antibodies increase progression risk to overt disease. Additionally, lipid profiling is recommended, given associations with elevated cholesterol and triglycerides that heighten cardiovascular concerns in this population. During pregnancy, hypothyroidism diagnosis must account for trimester-specific TSH adjustments, with the first trimester upper threshold lowered to 2.5 mU/L (reference range 0.1-2.5 mU/L) due to physiological shifts. Human chorionic gonadotropin (hCG), peaking in early gestation, exerts thyrotropic effects by binding to TSH receptors, suppressing maternal TSH and potentially complicating interpretation of low-normal values. Subsequent trimesters see gradual normalization, with upper limits of 3.0 mU/L recommended, emphasizing the need for pregnancy-specific reference ranges to guide accurate assessment. In the post-COVID-19 era, emerging evidence highlights increased incidence of new-onset autoimmune thyroid disorders, including hypothyroidism, following SARS-CoV-2 infection, as documented in studies from 2023 to 2025. These cases often involve thyroiditis with autoantibody development, prompting recommendations for thyroid function monitoring in recovering patients, particularly those with lingering symptoms or risk factors for autoimmunity. Serial TSH and antibody testing can detect subclinical shifts early. Congenital hypothyroidism screening relies on universal newborn protocols, typically involving TSH measurement via heel-prick dried blood spots collected between 48 and 72 hours of life to capture postnatal surges. Elevated TSH above 40 mU/L triggers immediate recall for confirmatory serum TSH and FT4 testing, enabling prompt intervention to prevent neurodevelopmental deficits. For preterm or low-birth-weight infants at higher false-positive risk, guidelines advocate repeat screening around 2 weeks of age or simultaneous TSH/FT4 evaluation to mitigate delayed elevations.Differential Diagnosis
The symptoms of hypothyroidism, such as fatigue, weight gain, depression, constipation, and cold intolerance, are nonspecific and overlap with those of many other conditions. Primary hypothyroidism is confirmed by elevated TSH and low free T4 levels. However, if symptoms persist despite normal or treated thyroid function tests, or if laboratory findings are atypical or nonspecific, other disorders should be considered in the differential diagnosis.[11][71] Common conditions that may mimic hypothyroidism include:- Depression
- Anemia (e.g., iron deficiency anemia)
- Chronic fatigue syndrome
- Fibromyalgia
- Obstructive sleep apnea
- Adrenal insufficiency (e.g., Addison disease)
- Non-thyroidal illness syndrome (euthyroid sick syndrome)
- Drug-induced effects (e.g., lithium)
- Hypopituitarism
